



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## AC-264613

Cat. No.:	HY-14351
CAS No.:	1051487-82-1
Molecular Formula:	C <sub>19</sub> H <sub>18</sub> BrN <sub>3</sub> O <sub>2</sub>
Molecular Weight:	400.27
Target:	Protease Activated Receptor (PAR)
Pathway:	GPCR/G Protein
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 40 mg/mL (99.93 mM)  
\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.4983 mL	12.4916 mL	24.9831 mL
	5 mM	0.4997 mL	2.4983 mL	4.9966 mL
	10 mM	0.2498 mL	1.2492 mL	2.4983 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

AC-264613 is a potent and selective protease-activated receptor (PAR-2) agonist with a pEC<sub>50</sub> of 7.5<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

pEC<sub>50</sub>: 7.5 (PAR-2)<sup>[1]</sup>

#### In Vitro

AC-264613 (10 μM; for 6 hours) causes a decrease of IRF5 expression and also significantly reduces p53 protein expression in macrophages<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis<sup>[2]</sup>

Cell Line:	Granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent macrophages
Concentration:	10 μM
Incubation Time:	6 hours
Result:	Significantly decreased IRF5 expression and reduced p53 protein levels.

**In Vivo**

AC-264613 exhibits moderate elimination half-life ( $T_{1/2}=2.5\pm 2.0$  h) following i.p. administration (10 mg/kg) in male Sprague-Dawley rats<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**REFERENCES**

- [1]. Jimmi Gerner Seitzberg, et al. Discovery of potent and selective small-molecule PAR-2 agonists. *J Med Chem.* 2008 Sep 25;51(18):5490-3.
- [2]. Rui Yamaguchi, et al. A protease-activated receptor 2 agonist (AC-264613) suppresses interferon regulatory factor 5 and decreases interleukin-12p40 production by lipopolysaccharide-stimulated macrophages: Role of p53. *Cell Biol Int.* 2016 Jun;40(6):629-41
- [3]. Luis R Gardell, et al. Identification and characterization of novel small-molecule protease-activated receptor 2 agonists. *J Pharmacol Exp Ther.* 2008 Dec;327(3):799-808.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA